Goldman Sachs
DFTX

Goldman Sachs’s Definium Therapeutics DFTX Stock Holding History

Goldman Sachs’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$84.7M Buy
1,800,852
+125,441
+7% +$3.1M 0.01% 1361
2026
Q1 		$31.7M Buy
1,675,411
+750,079
+81% +$12.7M ﹤0.01% 2002
2025
Q4 		$12.4M Buy
925,332
+374,702
+68% +$4.64M ﹤0.01% 2876
2025
Q3 		$6.49M Buy
550,630
+447,783
+435% +$4.18M ﹤0.01% 3406
2025
Q2 		$667K Sell
102,847
-89,348
-46% -$588K ﹤0.01% 4979
2025
Q1 		$1.12M Sell
192,195
-104,611
-35% -$749K ﹤0.01% 4592
2024
Q4 		$2.07M Buy
296,806
+126,857
+75% +$873K ﹤0.01% 4250
2024
Q3 		$967K Buy
169,949
+100,435
+144% +$699K ﹤0.01% 4658
2024
Q2 		$501K Sell
69,514
-338,486
-83% -$2.96M ﹤0.01% 4831
2024
Q1 		$3.84M Buy
408,000
+296,069
+265% +$1.69M ﹤0.01% 3337
2023
Q4 		$410K Buy
111,931
+85,025
+316% +$256K ﹤0.01% 4864
2023
Q3 		$84.2K Buy
26,906
+11,090
+70% +$45.6K ﹤0.01% 5207
2023
Q2 		$56.5K Hold
15,816
– – ﹤0.01% 5453
2023
Q1 		$50.1K Sell
15,816
-71,045
-82% -$236K ﹤0.01% 5551
2022
Q4 		$191K Buy
86,861
+71,056
+450% +$197K ﹤0.01% 5322
2022
Q3 		$55K Sell
15,805
-1,614
-9% -$15.5K ﹤0.01% 5790
2022
Q2 		$167K Sell
17,419
-5,766
-25% -$73K ﹤0.01% 5701
2022
Q1 		$386K Buy
23,185
+7,938
+52% +$138K ﹤0.01% 5502
2021
Q4 		$316K Sell
15,247
-52,487
-77% -$1.68M ﹤0.01% 5644
2021
Q3 		$2.37M Buy
67,734
+49,479
+271% +$2.14M ﹤0.01% 4031
2021
Q2 		$944K Buy
+18,255
New +$958K ﹤0.01% 4808

Other funds holding DFTX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Goldman Sachs's DFTX Position: Q2 2026 in Review

Goldman Sachs increased its Definium Therapeutics (DFTX) stake by 7.5% in Q2 2026, buying an estimated $3.1M and bringing the position to 1,800,852 shares worth $84.7M. The position accounts for 0.01% of the portfolio, ranked #1361.

Goldman Sachs first reported a position in DFTX in Q2 2021 and has held it in 21 quarters since. 362 funds tracked by Wall St. Rank hold DFTX as of Q2 2026.

  • Goldman Sachs held 1,800,852 shares of Definium Therapeutics worth $84.7M as of Q2 2026.
  • Goldman Sachs bought 125,441 Definium Therapeutics shares in Q2 2026, an estimated $3.1M.
  • Definium Therapeutics made up 0.01% of Goldman Sachs's portfolio in Q2 2026, its #1361 holding.
  • Goldman Sachs first reported a position in Definium Therapeutics in Q2 2021 and has held it in 21 quarters since.
  • 362 funds tracked by Wall St. Rank held Definium Therapeutics as of Q2 2026.

Based on Goldman Sachs's 13F filing for Q2 2026, filed 14 Aug 2026.